Metastatic adrenocortical carcinoma treated with sunitinib: a case report

Jpn J Clin Oncol. 2009 Mar;39(3):183-5. doi: 10.1093/jjco/hyn146. Epub 2009 Jan 24.


Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis. Palliative chemotherapy can be considered in patients with metastatic disease. Although mitotane- or cisplatin-based chemotherapy regimens are widely used, the effects of these agents have been limited. We have experienced a case that showed a partial response with sunitinib after failure of mitotane-based cytotoxic chemotherapy. The clinical benefit from sunitinib persisted 7.5 months in this case. To our knowledge, this is the first reported case showing the effects of sunitinib on metastatic ACC.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Cortex Neoplasms / drug therapy*
  • Adrenal Cortex Neoplasms / pathology*
  • Angiogenesis Inhibitors / therapeutic use
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma / drug therapy*
  • Carcinoma / secondary*
  • Drug Resistance, Neoplasm
  • Humans
  • Indoles / therapeutic use*
  • Male
  • Mitotane / administration & dosage
  • Pyrroles / therapeutic use*
  • Radiotherapy, Adjuvant
  • Sunitinib
  • Treatment Failure
  • Treatment Outcome
  • Young Adult


  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Indoles
  • Pyrroles
  • Mitotane
  • Sunitinib